Prevention of Preterm Birth in Pregnant Women at Risk Identified by Ultrasound: Evaluation of Two Treatment Strategies (PESAPRO)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01643980 |
|
Recruitment Status :
Completed
First Posted : July 18, 2012
Last Update Posted : October 17, 2016
|
Sponsor:
Dra.Cristina Martinez Payo
Information provided by (Responsible Party):
Dra.Cristina Martinez Payo, Puerta de Hierro University Hospital
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The preterm birth is considered as a main problem in the modern obstetrics, being the responsible of greatest of 50% neonatal morbimortality and heavy costs. Despite the significant medical advances, the rate of prematurity has not declined over the past 40 years and even continues to rise in the developed countries. In order to decrease the prematurity is necessary that two premises: to identify the pregnant women at risk of preterm birth, and dispose of useful measures aimed at prolonging the pregnancy and therefore avoid preterm delivery. The investigators propose a clinical trial with the objective to identify effective strategies to reduce the premature birth (34 weeks and earlier) rate in the population of pregnant women at risk for premature birth, which will be identified by ultrasound during the second trimester of their pregnancy.
The investigators intend to compare two accepted strategies: administration of progesterone (vaginally) or the placement of vaginal pessaries. These 2 strategies are affordable, easy to apply, and they present very few maternal-fetal secondary effects.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Early Onset of Delivery Before 37 Weeks | Drug: Vaginal micronized progesterone Device: Cervical pessary | Phase 4 |
The preterm birth is considered as a main problem in the modern obstetrics, being the responsible of greatest of 50% neonatal morbimortality and heavy costs. Despite the significant medical advances, the rate of prematurity has not declined over the past 40 years and even continues to rise in the developed countries. In order to decrease the prematurity is necessary that two premises: to identify the pregnant women at risk of preterm birth, and dispose of useful measures aimed at prolonging the pregnancy and therefore avoid preterm delivery. Since 1990, many published articles describe the sonographic measurement of the cervix from the week 16 as method of population screening to detect women at risk. Several studies provide evidence about an inverse relationship between the cervical length and the risk of preterm delivery. For this reason, if there is an effective intervention for patients with cervix short (about < 25mm), made this measure in the middle of the second term, the investigators could reduce the prematurity. Regarding possible therapeutic strategies, recent published data demonstrate the effective of vaginal progesterone and cervical pessary in this population. However, both treatments have never been compared and none of the two strategies are indicated in this population. Therefore it results necessary to compare both treatments in order to establish clinical recommendations. The investigators propose a clinical trial to compare two accepted strategies: administration of progesterone (vaginally) or the placement of vaginal pessaries in order to reduce the premature birth (34 weeks and earlier) rate in the population of pregnant women at risk for premature birth, which will be identified by ultrasound during the second trimester of their pregnancy.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 254 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Prevention |
| Official Title: | Prevention of Preterm Birth in Pregnant Women at Risk Identified by Ultrasound: Evaluation of Two Treatment Strategies |
| Study Start Date : | August 2012 |
| Actual Primary Completion Date : | March 2016 |
| Actual Study Completion Date : | April 2016 |
Resource links provided by the National Library of Medicine
Drug Information available for:
Progesterone
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Vaginal micronized progesterone
200 mg vaginal route per day
|
Drug: Vaginal micronized progesterone
200 mg vaginal route per day |
|
Active Comparator: Cervical pessary
Cervical pessary certified by European Conformity (CE0482, MED/CERT ISO 9003/EN 46003;Dr Arabin, lower larger diameter 70 mm, height 30 mm,and upper smaller diameter 32 mm)
|
Device: Cervical pessary
Cervical pessary certified by European Conformity (CE0482, MED/CERT ISO 9003/EN 46003;Dr Arabin, lower larger diameter 70 mm, height 30 mm,and upper smaller diameter 32 mm) |
Primary Outcome Measures :
- Proportion of spontaneous preterm birth before 34 weeks of gestation [ Time Frame: up to 11 weeks (from date of randomization until delivery) ]
Secondary Outcome Measures :
- Proportion of spontaneous preterm birth before 37 weeks of gestation [ Time Frame: up to 17 weeks (from date of randomization until delivery) ]
- Proportion of Spontaneous preterm birth before 28 weeks of gestation [ Time Frame: up to 8 weeks (from date of randomization until delivery) ]
- Rate of premature rupture of membranes before 34 weeks of gestation [ Time Frame: up to 11 weeks (from date of randomization until delivery) ]
- Weight at birth [ Time Frame: up to 21 weeks (from date of randomization until delivery) ]
- Rate of fetal and neonatal mortality [ Time Frame: From date of randomization until the date of delivery, assessed up 21 weeks ]
- Symptomatic vaginal infections during treatment period [ Time Frame: From date of randomization until the date of delivery, assessed up 21 weeks ]
- Proportion of participants with adverse events [ Time Frame: From date of randomization until the date of delivery, assessed up 21 weeks ]
- Rate of Chorioamnionitis during third term [ Time Frame: From date of randomization until the date of delivery, assessed up 21 weeks ]
- Need of admission because of premature labor before 34 weeks of gestation [ Time Frame: up to 14 weeks (from date of randomization until delivery) ]
- Rate of neonatal morbidity [ Time Frame: From date of randomization until the date of delivery, assessed up 21 weeks ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Pregnant women with short cervix (=< 25 mm) identified by use of routine transvaginal ultrasonography at 19-22 weeks of gestation.
- Single pregnancy
- Women older than 18 year-old
- Women sign informed consent according GCP and local legislation
- Gestational age at randomization between 20+1 and 23+6 weeks.
Exclusion Criteria:
- Major fetal abnormalities
- Major uterine abnormalities
- Placenta praevia during current pregnancy
- Vaginal bleeding or ruptured membranes in the moment of randomization
- Cervical cerclage in situ
- History of cone biopsy
- Allergic to peanuts
- Contraindication for Progesterone usage.
- Active treatment with Progesterone at randomization.
- History of 3 or more premature labor.
- If in the investigator's opinion, there are findings on physical examination, abnormalities in the results of clinical analyzes or other medical factors, social or psycho-social that could negatively influence.
- Women unable to give the informed consent
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01643980
Locations
Show 27 study locations
Sponsors and Collaborators
Dra.Cristina Martinez Payo
Investigators
| Principal Investigator: | Sara Cruz Melguizo, Dr | University Hospital Puerta de Hierro Majadahonda | |
| Principal Investigator: | Cristina Martinez Payo, Dr. | University Hospital Puerta de Hierro Majadahonda |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Dra.Cristina Martinez Payo, Principal Investigator, Puerta de Hierro University Hospital |
| ClinicalTrials.gov Identifier: | NCT01643980 |
| Other Study ID Numbers: |
PESAPRO-2012 2012-000241-13 ( EudraCT Number ) |
| First Posted: | July 18, 2012 Key Record Dates |
| Last Update Posted: | October 17, 2016 |
| Last Verified: | October 2016 |
Additional relevant MeSH terms:
|
Premature Birth Obstetric Labor, Premature Obstetric Labor Complications Pregnancy Complications Progesterone |
Progestins Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs |